As policy reform reshapes how care is paid for and delivered, this panel explores where population health is heading and where investors see opportunity. Experts will discuss how recent policy changes are exposing long-standing inefficiencies in a system built around fee-for-service, and how those gaps are creating new openings for investment. At the same time, advances in AI and technology are helping providers and payers engage patients, improve quality, lower costs, and ease workforce shortages, changing where investors can make the greatest impact on the healthcare industry. Discussion will center on provider-led MSOs, advanced primary care (APCM), ACO evolution (ACO LEAD), dementia care (GUIDE), rural health support (RHTF), behavioral health investments, and interoperability and data-sharing mandates. Beyond these areas, panelists will highlight emerging opportunities drawing regulatory attention and investor interest. They will also share where they are focusing within population health and where they predict future policy.

Speaker information coming soon.

AI is transforming industries, and biopharma is no exception. AI has the potential to deliver better drugs more efficiently to patients. Some advocates predict all human diseases will be solved with AI within a decade. Others believe longer, and that it will exacerbate the industry's R&D problems by flooding the pipeline with early-stage candidates faster than clinical development can digest them. These shifts raise new questions at every step of a drug’s path from lab to patient: where a biotech’s real advantage comes from when AI can generate molecules quickly, what proof investors need before backing an AI-driven team, and what a pharma acquirer is actually paying for in an AI-native company, whether the candidates, the data, or the people.

This panel brings together all three sides of a single success story: founding members of an AI-enabled biotech, the venture firm that first backed them, and the pharma team that acquired them. Together, they will trace the company’s journey from first molecule to acquisition and discuss where their views of its value aligned and where they differed. Expect candid discussion of how each side judged the same company, and what it takes for AI-discovered medicines to reach patients faster.

Speaker information coming soon.

As drugmakers sell more medicines directly to patients and employers, insurance is becoming one path to a prescription rather than the only one. This shift is reshaping strategy across the industry: how manufacturers plan their go-to-market and patient support, how payers design benefits, and how PBMs manage care across channels. But getting the medicine is only the first step. This panel brings together leaders from pharma, payers, PBMs and direct-to-consumer health to discuss how these strategies are evolving, and how the industry can make sure patients stay on therapy, stay connected to their care, and are better off when a prescription is filled outside the traditional benefit.

Speaker information coming soon.

AI is easy to claim in healthcare and much harder to prove. Health systems, payers, and clinicians field no shortage of AI pitches, but only a fraction earn a place in the workflow, the budget, or the exam room. This panel brings together founders building AI-first companies at different stages to discuss how they have earned belief from investors, from buyers, and from the clinicians who have to use their products. Topics include what proof looks like at seed versus Series B, how to find product-market fit when the user, the buyer, and the payer are often different people, when a tool stops being a workflow convenience and starts improving patient care, and how to earn trust when building on patient data. Underneath it all is the question this year’s theme asks of the whole system: does AI give clinicians time back to spend with patients, or just add another tool to the stack? Expect candid discussion of what has worked, what hasn’t, and what it takes for AI to move care toward the patient.

Speaker information coming soon.

As rising healthcare costs and new technologies drive care beyond hospitals into outpatient clinics, community health centers, and patients’ homes, value-based care is gaining renewed attention as a way to make this shift more affordable and sustainable. With the launch of CMS’s new LEAD model in 2027 and the recent introduction of ACCESS, this panel explores how payers, providers, and technology innovators can make delivering care outside hospitals financially viable while improving patient outcomes. Topics include funding community-based and home-based care, sharing financial risk across providers, using technology to improve care coordination, and the impact of new payment models on healthcare access, affordability, and quality.

Speaker information coming soon.

Women’s health needs remain under-researched and underserved across the care journey. Women have historically been underrepresented in clinical trials, symptoms are too often dismissed or misattributed, and care is frequently fragmented across specialties that rarely talk to one another. The result is gaps at nearly every life stage, from reproductive years to midlife and beyond. However, recent events, including the FDA’s move to remove boxed warnings from menopausal hormone therapies and the global consensus to reclassify PCOS as PMOS, have prompted a shift in momentum across clinicians and healthcare organizations to assess how care can be reoriented around women.

This panel will explore what that shift looks like in practice, from menopause and postpartum mental health to fertility considerations in cancer care and the new understanding of PMOS as a lifelong metabolic and endocrine condition. These are areas where unmet need is high, evidence is still catching up, and the right support at the right moment can change outcomes for years to come. Panelists will discuss how they are building services that are more responsive to women’s needs, how they are generating and applying evidence where it has been thin, and what it takes to bring clinical, operational, and business stakeholders together around moving these priorities forward.

Speaker information coming soon.